Background: PCSK9 MaB (Proprotein Convertase Subtilisin/Kexin Type 9
Inhibitor) may reduce the occurrence of major adverse cardiovascular events
(MACEs) in patients diagnosed with acute coronary syndrome (ACS). In this
meta-analysis, we conducted a thorough compilation of evidence from established
clinical studies to evaluate PCSK9 MaB’s capacity to control blood lipid levels
and prevent MACEs in ACS patients. Methods: We conducted searches on
Pubmed, Embase, the Cochrane Library, and Web of Science to identify relevant
articles. Data from ACS patients were extracted using a standardized format for
aggregating data. We calculated the risk ratio (RR) for MACE and assessed changes
in blood lipid parameters. All statistical analyses were performed using RevMan.
Results: 11 articles representing 5 trials were included in our
systematic review and meta-analysis. When compared to a placebo, PCSK9 MaB
significantly reduced the risk of MACEs (I
Announcements
Open Access
Systematic Review
Efficacy and Safety of PSCK9 Inhibitors on Patients with Acute Coronary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials
Show Less
1
Graduate School, Nanjing University of Chinese Medicine, 210029 Nanjing, Jiangsu, China
2
Department of Cardiovascular, Wuxi Traditional Chinese Medicine Hospital, 214071 Wuxi, Jiangsu, China
*Correspondence: wxzy001@njucm.edu.cn (Shu Lu)
Rev. Cardiovasc. Med. 2024, 25(3), 94;
https://doi.org/10.31083/j.rcm2503094
Submitted: 1 September 2023 | Revised: 8 November 2023 | Accepted: 13 November 2023 | Published: 7 March 2024
Copyright: © 2024 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.
Abstract
Keywords
PSCK9I
acute coronary syndrome
systematic review
meta-analysis
Funding
82274427/Study on the biological network integration and regulation mechanism in the treatment of dilated cardiomyopathy with Linggui Yangxin Decoction
BK20201141/Study on the mechanism of Shenqi Yangxin Decoction to improve dilated cardiomyopathy by regulating DNA methylation involving DNMT1 to inhibit pyroptosis
BK20201141/Jiangsu Provincial Natural Science Foundation Project
Figures
Fig. 1.